Evlogi Itsev serves as the Executive Director of Marketing and New Product Commercial Leader at TRIS PHARMA INC, where he leverages his extensive background in both psychiatry and marketing to drive innovative strategies for product development and market penetration. With a robust foundation in clinical...
Evlogi Itsev serves as the Executive Director of Marketing and New Product Commercial Leader at TRIS PHARMA INC, where he leverages his extensive background in both psychiatry and marketing to drive innovative strategies for product development and market penetration. With a robust foundation in clinical practice, Evlogi brings a unique perspective to the pharmaceutical industry, allowing him to bridge the gap between medical insights and commercial viability. His current role involves leading cross-functional teams to evaluate and inform optimal development strategies for priority assets, particularly those in Phase III clinical trials.
One of Evlogi's key projects includes the creation and implementation of comprehensive market development plans that align with the strategic goals of the organization. Collaborating closely with the Brand Division President, he ensures the timely establishment of launch and commercialization strategies that resonate with healthcare providers and patients alike. His expertise in commercial model optimization and pricing strategies has been instrumental in enhancing brand awareness and driving growth for TRIS PHARMA's portfolio.
Evlogi's proficiency in market research and competitive pricing analysis enables him to identify emerging trends and opportunities within the neurology sector, positioning TRIS PHARMA as a leader in innovative therapeutic solutions. His leadership skills foster a collaborative environment where cross-functional teams can thrive, ultimately contributing to the successful launch of new products and the sustained performance of in-line brands. With a commitment to excellence and a passion for improving patient outcomes, Evlogi Itsev continues to make significant contributions to the pharmaceutical landscape.
